Exploring RNA biology in pseudomyxoma peritonei uncovers splicing dysregulation as a novel, targetable molecular...

Area of Science:

• Oncology
• Molecular Biology
• RNA Biology

Background:

• Pseudomyxoma peritonei (PMP) is a rare malignancy characterized by extensive mucus accumulation and high recurrence rates.
• The role of RNA biology in PMP pathogenesis is largely unexplored, representing a knowledge gap in understanding this rare cancer.

Purpose of the Study:

• To investigate the involvement of RNA-regulatory machineries, including splicing, RNA exosome, and nonsense-mediated decay pathways, in the progression of PMP.
• To identify potential therapeutic targets within these RNA regulatory networks for PMP treatment.

Main Methods:

• Analysis of 62 splicing-related genes, 27 RNA exosome genes, and 21 nonsense-mediated decay genes in 29 PMP patients using microfluidic arrays.
• Comparison of tumor tissues with control tissues, integrated with external RNA-sequencing and proteomic data.
• In vitro experiments involving splicing inhibition with Pladienolide-B and modulation of splicing factors.

Main Results:

• Significant dysregulation of key RNA-regulatory genes was observed in PMP tumors, correlating with clinical parameters and differentiating tumor from control tissues.
• In vitro inhibition of splicing reduced PMP aggressiveness, enhanced the efficacy of existing drugs, and impacted mucin production.
• A strong correlation was found between dysregulated genes and established cancer-related genes, highlighting interconnected pathways.

Conclusions:

• This study provides the first evidence of widespread dysregulation in pivotal RNA-regulatory processes in pseudomyxoma peritonei.
• Targeting these altered RNA regulatory mechanisms presents a promising avenue for developing novel therapeutic strategies and identifying actionable vulnerabilities in PMP.
• Understanding the RNA biology of PMP is crucial for advancing treatment options for this rare and challenging disease.